Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
|
30544063 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model.
|
31336121 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we revealed that CASC2, a well-established tumor suppressive long non-coding RNA, could serve as a "Sponge" of miR-24 and miR-221, thus modulating TRAIL-induced tumor cell apoptosis TRAIL resistance of hepatocellular carcinoma.
|
29476051 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate chloroquine's (CQ) ability to trigger TRAIL/TRAILR2 apoptotic pathway in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) either alone or in combination with doxorubicin (DOX).
|
29133031 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidence has shown that most hepatocellular carcinoma (HCC) cells are resistant to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.
|
29444104 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice.
|
28885731 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Synergistic Anti-tumour Effects of Quercetin and Oncolytic Adenovirus expressing TRAIL in Human Hepatocellular Carcinoma.
|
29391509 |
2018 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein we investigated the antitumor activity and safety of mono- and combined therapy with OAds armed with ING4 (Ad-ΔB/ING4) and TRAIL (Ad-ΔB/TRAIL) gene, respectively, on preclinical models of human HCC.
|
28925992 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, whether such change of miRNA on TRAIL sensitivity is seen in hepatocellular carcinoma still needs to be explored.
|
28410209 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, authors introduced new integration between gene therapy and nanotechnology in the form of PTEN and TRAIL-loaded ZNPs that proved potential to be used in gene therapy for the treatment of HCC.
|
28140697 |
2017 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms.
|
27154307 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the cancer stem cells (CSCs) are believed to be responsible for the treatment failure in multiple cancers including hepatocellular carcinoma (HCC), the aim of this study was to investigate the strategies to increase the sensitivity of liver cancer stem cells (LCSCs) to TRAIL.
|
27840896 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Correlation analysis revealed significantly lower TRAIL expression in HCC samples with the -1573C sequence (P ≤ 0.05).
|
27580702 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forced expression of Msi1 decreased the sensitivity of HCC cells to TRAIL both in vitro and in vivo.
|
25747387 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidence has shown HCC cell resistance to TRAIL‑mediated apoptosis.
|
25607597 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of this study suggest that low TRAIL mRNA levels may be both a dominant feature in HCC development and growth and a predictor of tumor recurrence and poorer survival rates.
|
25123818 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, experiments in both hepatocellular carcinoma and melanoma-bearing mice demonstrated that the genetically engineered rNDV-IL-2-TRAIL exhibited prolonged animals' survival compared with rNDV, rNDV-IL-2, and rNDV-TRAIL.
|
24971746 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, the results of the present study indicate that BM-MSC can provide a steady source of stTRAIL and may be suitable for use in the prevention of the recurrence of hepatocellular carcinoma after RFA with secretable trimeric TRAIL.
|
24451114 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although TRAIL and its receptors are selective targets for cancer therapy, their potential against HCC with chronic HCV infection has not been explored yet.
|
24927176 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to explore whether Gli2 silencing enhances efficiency of TRAIL for hepatoma in vivo.
|
25535898 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insights from TRAIL mediated signaling in HCC research are catalyzing new lines of study that should not only explain molecular mechanisms of disease but also highlight emerging paradigms in restoration of TRAIL mediated apoptosis in resistant cancer cells.
|
25037270 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ABT-263, a second-generation BH3 mimic, binds to the anti-apoptotic family members Bcl-2, Bcl-xL and Bcl-w, and has been demonstrated to enhance TNFSF10 (TRAIL)-induced apoptosis in human hepatocarcinoma cells.
|
24571452 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fn14•TRAIL induced robust apoptosis of multiple HCC cell lines, while sparing non-malignant hepatocyte cell lines.
|
24130833 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The novel CTL harboring Lenti/hCD40L/E1AB and Ad5/35-TRAIL caused proliferation inhibition and significant apoptosis in hepatocellular carcinoma cell lines.
|
23825554 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results in human hepatocarcinoma cell lines and primary hepatocytes provide a rationale for testing the combination of salirasib and TRAIL agonists in human hepatocarcinoma.
|
23348585 |
2013 |